# Mettler Toledo International Inc/: Form 10-Q for the period ended Jun 30, 2018

- Company: [Mettler Toledo International Inc/](/companies/mtd.md) (CIK 1037646)
- Form: 10-Q
- Filed: 2018-07-27
- Accepted by EDGAR: Jul 27, 2018, 09:03 ET
- Period: 2018-06-30
- Accession: 0001037646-18-000026
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1037646/000103764618000026/mtd10q63018.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1037646/000103764618000026/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2018-04-01 to 2018-06-30 | $722.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2018-01-01 to 2018-06-30 | $1.38bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Gross profit | 3 months, 2018-04-01 to 2018-06-30 | $412.6m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2018-01-01 to 2018-06-30 | $787.6m | us-gaap:GrossProfit |
| Research and development | 3 months, 2018-04-01 to 2018-06-30 | $35.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2018-01-01 to 2018-06-30 | $70.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2018-04-01 to 2018-06-30 | $208.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2018-01-01 to 2018-06-30 | $408.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months, 2018-04-01 to 2018-06-30 | $8.3m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2018-01-01 to 2018-06-30 | $16.7m | us-gaap:InterestExpense |
| Income tax | 3 months, 2018-04-01 to 2018-06-30 | $32.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2018-01-01 to 2018-06-30 | $56.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2018-04-01 to 2018-06-30 | $111.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2018-01-01 to 2018-06-30 | $204.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2018-04-01 to 2018-06-30 | $4.31 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2018-01-01 to 2018-06-30 | $7.88 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2018-04-01 to 2018-06-30 | $4.41 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2018-01-01 to 2018-06-30 | $8.07 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2018-04-01 to 2018-06-30 | 25,867,383 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2018-01-01 to 2018-06-30 | 25,979,508 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2018-01-01 to 2018-06-30 | $216.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2018-01-01 to 2018-06-30 | $61.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months, 2018-01-01 to 2018-06-30 | $237.5m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2018-06-30 | $183.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2018-06-30 | $1.00bn | us-gaap:AssetsCurrent |
| Total assets | at 2018-06-30 | $2.56bn | us-gaap:Assets |
| Current liabilities | at 2018-06-30 | $688.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2018-06-30 | $2.03bn | us-gaap:Liabilities |
| Long-term debt | at 2018-06-30 | $1.02bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2018-06-30 | $52.1m | us-gaap:DebtCurrent |
| Shareholders' equity | at 2018-06-30 | $532.4m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2018-06-30 | 25,213,828 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 32,057 characters.

*The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the Unaudited Interim Consolidated Financial Statements included herein.*

### General

Our interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. Operating results for the three and six months ended June 30, 2018 are not necessarily indicative of the results to be expected for the full year ending December 31, 2018.

Changes in local currency exclude the effect of currency exchange rate fluctuations. Local currency amounts are determined by translating current and previous year consolidated financial information at an index utilizing historical currency exchange rates. We believe local currency information provides a helpful assessment of business performance and a useful measure of results between periods. We do not, nor do we suggest that investors should, consider such non-GAAP financial measures in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. We present non-GAAP financial measures in reporting our financial results to provide investors with an additional analytical tool to evaluate our operating results.

We also include in the discussion below disclosures of immaterial qualitative factors that are not quantified. Although the impact of such factors is not considered material, we believe these disclosures can be useful in evaluating our operating results.

### Results of Operations – Consolidated

The following tables set forth certain items from our interim consolidated statements of operations for the three and six month periods ended June 30, 2018 and 2017 (amounts in thousands).

|  | Three months ended June 30, 2018 (unaudited)% |  | 2017 (unaudited)% |  | Six months ended June 30, 2018 (unaudited)% |  | 2017 (unaudited)% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net sales | $721,996 | 100.0 | $653,656 | 100.0 | $1,382,817 | 100.0 | $1,248,223 | 100.0 |
| Cost of sales | 309,371 | 42.8 | 278,044 | 42.5 | 595,259 | 43.0 | 529,222 | 42.4 |
| Gross profit | 412,625 | 57.2 | 375,612 | 57.5 | 787,558 | 57.0 | 719,001 | 57.6 |
| Research and development | 35,315 | 4.9 | 32,582 | 5.0 | 70,028 | 5.1 | 63,782 | 5.1 |
| Selling, general and administrative | 208,024 | 28.8 | 195,624 | 29.9 | 408,698 | 29.6 | 381,280 | 30.5 |
| Amortization | 11,970 | 1.7 | 10,249 | 1.6 | 23,705 | 1.7 | 20,294 | 1.6 |
| Interest expense | 8,309 | 1.2 | 8,171 | 1.3 | 16,668 | 1.2 | 15,912 | 1.3 |
| Restructuring charges | 7,321 | 1.0 | 4,023 | 0.6 | 11,734 | 0.8 | 5,455 | 0.4 |
| Other charges (income), net | (1,916) | (0.3) | (1,884) | (0.3) | (4,316) | (0.3) | (8,417) | (0.6) |
| Earnings before taxes | 143,602 | 19.9 | 126,847 | 19.4 | 261,041 | 18.9 | 240,695 | 19.3 |
| Provision for taxes | 32,134 | 4.5 | 25,267 | 3.9 | 56,269 | 4.1 | 46,649 | 3.8 |
| Net earnings | $111,468 | 15.4 | $101,580 | 15.5 | $204,772 | 14.8 | $194,046 | 15.5 |

#### Net sales

Net sales were $722.0 million and $653.7 million for the three months ended June 30, 2018, and 2017, and $1.4 billion and $1.2 billion for the six months ended June 30, 2018 and June 30, 2017, respectively. This represents an increase of 10% and 11% in U.S. dollars for the three and six months ended June 30, 2018. Excluding the effect of currency exchange rates fluctuations, or in local currencies, net sales increased 7% and 6% for the three and six months ended June 30, 2018. The Biotix acquisition contributed approximately 1.5% to local currency net sales for both the three and six months ended June 30, 2018. These results compare to 10% and 11% local currency growth for the three and six months ended June 30, 2017 of which the Troemner acquisition contributed approximately 2% and 1%, respectively. Global market conditions were generally favorable during the first half of 2018 and we continue to benefit from the execution of our global sales and marketing programs, our robust product portfolio, and investments in our field resources. However, we remain cautious as market conditions are subject to change and economic uncertainties exist in certain regions of the world. We will also face a difficult prior period comparison in China during the second half of 2018.

Net sales by geographic destination for the three and six months ended June 30, 2018 in U.S. dollars increased in the Americas 4% and 5%, in Europe 14% and 13%, and in Asia/Rest of World 15% and 16%, respectively. Our net sales by geographic destination for the three and six months ended June 30, 2018 in local currencies increased in the Americas 4% and 5%, in Europe 7% and 3%, and in Asia/Rest of World 9% and 10%, respectively. The Biotix acquisition contributed approximately 2.5% to our local currency net sales growth in the Americas for both the three and six months ended June 30, 2018. A discussion of sales by operating segment is included below.

As described in Note 17 to our consolidated financial statements for the year ended December 31, 2017, our net sales comprise product sales of precision instruments and related services. Service revenues are primarily derived from repair and other services, including regulatory compliance qualification, calibration, certification, preventative maintenance and spare parts.

Net sales of products increased 10% in U.S. dollars and 6% in local currencies for the three months ended June 30, 2018 and increased 11% in U.S. dollars and 6% in local currencies for the six months ended June 30, 2018, compared to the corresponding periods in 2017. The Biotix acquisition contributed approximately 2% to our net sales of products for both the three and six months ended June 30, 2018. Service revenue (including spare parts) increased by 13% in U.S. dollars and 10% in local currencies for the three months ended June 30, 2018 and increased 11% in U.S. dollars and 6% in local currencies for the six months ended June 30, 2018, compared to the corresponding periods in 2017.

Net sales of our laboratory products and services, which represented approximately 51% of our total net sales increased 14% in U.S. dollars and 10% in local currencies for the three months ended June 30, 2018, and increased 15% in U.S. dollars and 10% in local currencies for the six months ended June 30, 2018. The local currency increase in net sales of our laboratory products includes solid growth in most product categories, especially process analytics. The Biotix acquisition also contributed approximately 3% to our growth of laboratory products and services for both the three and six months ended June 30, 2018.

Net sales of our industrial products and services, which represented approximately 41% of our total net sales increased 6% in U.S. dollars and 3% in local currencies for the three months ended June 30, 2018, and increased 6% in U.S. dollars and 1% in local currencies for the six months ended June 30, 2018. The local currency increase in net sales of our industrial products includes strong growth in core-industrial, offset in part by a decline in product inspection which had strong growth in the prior year comparable periods.

Net sales in our food retailing products and services, which represented approximately 8% of our total net sales increased 11% in U.S. dollars and 6% in local currencies for the three months ended June 30, 2018, and increased 9% in U.S. dollars and 3% in local currencies for the six months ended June 30, 2018. Food retailing included strong project activity in the Americas, offset by reduced net sales in Europe which had strong growth in the prior year six month period.

#### Gross profit

Gross profit as a percentage of net sales was 57.2% and 57.5% for the three months ended June 30, 2018 and 2017, and 57.0% and 57.6% for the six months ended June 30, 2018 and 2017, respectively.

Gross profit as a percentage of net sales for products was 60.6% and 61.1% for the three months ended June 30, 2018 and 2017, respectively, and 60.5% and 61.4% for the six months ended June 30, 2018 and 2017, respectively.

Gross profit as a percentage of net sales for services (including spare parts) was 45.1% and 44.3% for the three months ended June 30, 2018 and 2017, respectively, and 44.7% and 44.5% for the six months ended June 30, 2018 and 2017, respectively.

The decrease in gross profit as a percentage of net sales for the three and six months ended June 30, 2018 was primarily due to the impact of foreign currency translation, initial costs associated with a new manufacturing facility and the Biotix acquisition, offset in part by favorable price realization.

#### Research and development and selling, general and administrative expenses

Research and development expenses as a percentage of net sales was 4.9% and 5.0% for the three months ended June 30, 2018 and 2017, and was 5.1% for both the six months ended June 30, 2018 and 2017, respectively. Research and development expenses increased 9% in U.S. dollars and increased 6% in local currencies for the three months ended June 30, 2018, and increased 10% in U.S. dollars and increased 6% in local currencies for the six months ended June 30, 2018, respectively, compared to the corresponding periods in 2017 relating to increased project activity.

Selling, general and administrative expenses as a percentage of net sales were 28.8% and 29.9% for the three months ended June 30, 2018 and 2017, and was 29.6% and 30.5% for the six months ended June 30, 2018 and 2017, respectively. Selling, general and administrative expenses increased 6% in U.S. dollars and 3% in local currencies for the three months ended June 30, 2018, and increased 7% in U.S. dollars and 3% in local currencies for the six months ended June 30, 2018. The local currency increase includes investments in our field sales organization and growth initiatives, offset in part by benefits from our cost savings initiatives.

#### Amortization, interest expense, other charges (income), net and taxes

Amortization expense was $12.0 million and $10.2 million for the three months ended June 30, 2018 and 2017, respectively, and $23.7 million and $20.3 million for the six months ended June 30, 2018 and 2017, respectively.

Interest expense was $8.3 million and $8.2 million for the three months ended June 30, 2018 and 2017, respectively, and $16.7 million and $15.9 million for the six months ended June 30, 2018 and 2017, respectively.

Other charges (income), net includes non-service pension costs (benefits), (gains) losses from foreign currency transactions and related hedging activities, interest income and other items. Nonservice pension benefits was $1.5 million and $1.1 million for the three months ended June 30, 2018 and 2017, respectively, and $3.1 million and $1.9 million and for the six months ended June 30, 2018 and 2017, respectively. Other charges (income), net for the six months ended June 30, 2017 also includes a one-time gain of $3.4 million relating to the sale of a facility in Switzerland in connection with the our initiative to consolidate certain Swiss operations into a new facility.

Our reported tax rate was 22.4% and 19.9% during the three months ended June 30, 2018 and 2017, respectively and 21.6% and 19.4% during the six months ended June 30, 2018 and 2017, respectively. The increase in our reported tax rate for the three and six month periods is related to the timing of excess tax benefits associated with stock option exercises. The provision for taxes is based upon using our projected annual effective tax rate of 22.0% before non-recurring discrete tax items for the three and six months periods ended June 30, 2018. The difference between our projected annual effective tax rate of 22.0% and our reported tax rate is related to the timing of excess tax benefits associated with stock option exercises.

On December 22, 2017, the Tax Cuts and Jobs Act (the "Act") significantly revised U.S.corporate income tax law. The Act includes, among other things, a reduction in the U.S. federal corporate income tax rate from 35% to 21% effective for taxable years beginning after December 31, 2017, and the implementation of a modified territorial tax system that includes a one-time transition tax on deemed repatriated earnings of foreign subsidiaries ("Transition Tax") that is payable over a period of up to eight years.

Our accounting for the Act is based upon reasonable estimates, however, our estimates may

change upon the finalization of the Act's implementation and additional interpretive guidance from

regulatory authorities. Among other things, we need to complete our analysis of historical foreign

earnings and related taxes paid and our analysis of foreign cash equivalents. In addition, we need to

complete our analysis of deemed repatriation of deferred foreign income and related state tax effects. We will complete our accounting for the above tax effects of the Act during 2018 as provided in SAB 118 and will reflect any adjustments to our provisional amounts as an adjustment to the provision for taxes in the reporting period in which the amounts are finally determined.

### Results of Operations – by Operating Segment

The following is a discussion of the financial results of our operating segments. We currently have five reportable segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations and Other. A more detailed description of these segments is outlined in Note 17 to our consolidated financial statements for the year ended December 31, 2017.

#### U.S. Operations (amounts in thousands)

|  | Three months ended June 30, |  | Six months ended June 30, |  |
| --- | ---: | ---: | ---: | ---: |
|  | 2018 | 2017% | 2018 | 2017% |
| Total net sales | $274,961 | $261,923 5% | $528,372 | $499,689 6% |
| Net sales to external customers | $251,474 | $238,831 5% | $481,219 | $454,184 6% |
| Segment profit | $42,006 | $45,147 (7)% | $76,251 | $83,969 (9)% |

Total net sales and net sales to external customers both increased 5% for the three months ended June 30, 2018 compared with the corresponding period in 2017. Total net sales and net sales to external customers both increased 6% for the six months ended June 30, 2018 compared with the corresponding period in 2017. Net sales to external customers benefited approximately 4% from the Biotix acquisition for the three and six month periods ended June 30, 2018. The increase in total net sales and net sales to external customers for the three and six months ended June 30, 2018 reflects solid results in our laboratory products. We also experienced strong growth in retail due to the timing of project activity, offset in part by a decrease in product inspection related to particularly strong growth in the prior year periods.

Segment profit decreased $3.1 million and $7.7 million for the three and six months ended June 30, 2018, respectively, compared to the corresponding periods in 2017, primarily due to initial costs associated with a new manufacturing facility and continued investments in our field sales and service organization offset in part by benefits from our margin expansion initiatives.

#### Swiss Operations (amounts in thousands)

|  | Three months ended June 30, 2018 | 2017 | %1) | Six months ended June 30, 2018 | 2017 | %1) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Total net sales | $181,113 | $163,634 | 11% | $357,160 | $320,933 | 11% |
| Net sales to external customers | $32,154 | $32,287 | —% | $64,619 | $62,034 | 4% |
| Segment profit | $47,737 | $37,950 | 26% | $93,712 | $73,968 | 27% |

1\) Represents U.S. dollar growth (decline) for net sales and segment profit.

Total net sales increased 11% in U.S. dollars and 10% in local currency for the three months ended June 30, 2018, and increased 11% in U.S. dollars and 8% in local currency for the six months ended June 30, 2018 compared to the corresponding periods in 2017. Net sales to external customers were flat in U.S. dollars and decreased 1% in local currency for the three months ended June 30, 2018 and increased 4% in U.S. dollars and 2% in local currency for the six months ended June 30, 2018, compared to the corresponding periods in 2017. Local currency net sales to external customers for the three months ended June 30, 2018 includes strong growth in our core-industrial products, offset by a decrease in laboratory products. The increase in net sales to external customers for the six months ended June 30, 2018 includes growth in most product categories, especially core-industrial products.

Segment profit increased $9.8 million and $19.7 million for the three and six month periods ended June 30, 2018, compared to the corresponding periods in 2017. Segment profit during the three and six months ended June 30, 2018 includes the impact of increased net sales volume, our margin expansion initiatives and favorable foreign currency translation, offset in part by higher research and development activity.

#### Western European Operations (amounts in thousands)

|  | Three months ended June 30, 2018 | 2017 | %1) | Six months ended June 30, 2018 | 2017 | %1) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Total net sales | $218,913 | $195,044 | 12% | $425,297 | $385,309 | 10% |
| Net sales to external customers | $173,772 | $151,161 | 15% | $339,144 | $298,484 | 14% |
| Segment profit | $27,333 | $24,709 | 11% | $45,615 | $49,427 | (8)% |

1\) Represents U.S. dollar growth (decline) for net sales and segment profit.

Total net sales increased 12% in U.S. dollars and 4% in local currencies for the three months ended June 30, 2018 and increased 10% in U.S. dollars and decreased 1% in local currencies for the six months ended June 30, 2018, compared to the corresponding periods in 2017. Net sales to external customers increased 15% in U.S. dollars and increased 7% in local currencies for the three months ended June 30, 2018, and increased 14% in U.S. dollars and 2% in local currencies for the six months ended June 30, 2018, compared to the corresponding periods in 2017. Local currency net sales to external customers for the three and six months ended June 30, 2018 includes solid growth in most product categories, offset in part by declines in food retailing which faced very strong project activity in the prior six month period ended June 30, 2017.

Segment profit increased $2.6 million and decreased $3.8 million for the three and six month periods ended June 30, 2018, respectively, compared to the corresponding periods in 2017. The increase in segment profit for the three month period ended June 30, 2018 includes increased net sales volume, our margin expansion initiatives, and favorable currency translation, partially offset by higher research and development activity and an inter-segment product transfer. The decrease in segment profit for the six months ended June 30, 2018 also includes roll-in costs associated with our Blue Ocean program.

#### Chinese Operations (amounts in thousands)

|  | Three months ended June 30, 2018 | 2017 | %1) | Six months ended June 30, 2018 | 2017 | %1) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Total net sales | $191,860 | $165,128 | 16% | $366,197 | $308,842 | 19% |
| Net sales to external customers | $133,272 | $108,092 | 23% | $247,202 | $198,873 | 24% |
| Segment profit | $65,884 | $54,127 | 22% | $125,437 | $98,787 | 27% |

1\) Represents U.S. dollar growth for net sales and segment profit.

Total net sales increased 16% in U.S. dollars and 8% in local currency for the three months ended June 30, 2018 and increased 19% in U.S. dollars and 10% local currency for the six months ended June 30, 2018, compared to the corresponding periods in 2017. Net sales to external customers increased 23% in U.S. dollars and 15% in local currency for the three months ended June 30, 2018 and increased 24% in U.S. dollars and 16% local currency during the six months ended June 30, 2018, compared to the corresponding periods in 2017. The increase in local currency net sales to external customers during the three and six months ended June 30, 2018 reflects very strong growth in most product categories, especially laboratory products. While Chinese market conditions are currently favorable we will face difficult prior period comparisons during the remainder of 2018 due to our strong performance in 2017. In addition to the tough comparisons the Chinese economy has historically been volatile and market conditions may change unfavorably due to various factors.

Segment profit increased $11.8 million and $26.7 million for the three and six month periods ended June 30, 2018, respectively, compared to the corresponding periods in 2017. The increase in segment profit for the three and six months ended June 30, 2018 includes increased local currency net sales volume and benefits from our margin expansion and cost savings initiatives, and favorable foreign currency translation.

#### Other (amounts in thousands)

|  | Three months ended June 30, 2018 | 2017 | %1) | Six months ended June 30, 2018 | 2017 | %1) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Total net sales | $132,787 | $125,414 | 6% | $253,736 | $238,374 | 6% |
| Net sales to external customers | $131,324 | $123,285 | 7% | $250,633 | $234,648 | 7% |
| Segment profit | $17,642 | $15,181 | 16% | $31,523 | $28,289 | 11% |

1\) Represents U.S. dollar growth for net sales and segment profit.

Total net sales increased 6% in U.S. dollars and 3% in local currencies for the three months ended June 30, 2018 and increased 6% in U.S. dollars and 2% in local currencies for the six months ended June 30, 2018, compared to the corresponding periods in 2017. Net sales to external customers increased 7% in U.S. dollars and 4% in local currencies for the three months ended June 30, 2018 and increased 7% in U.S. dollars and 2% in local currencies for the six months ended June 30, 2018, compared to the corresponding periods in 2017. Local currency sales growth reflects growth in laboratory products offset by declines in food retailing and product inspection related which had strong project activity in the prior year periods.

Segment profit increased $2.5 million and $3.2 million for the three and six months ended June 30, 2018, respectively, compared to the corresponding periods in 2017.The increase in segment profit is primarily due to benefits from our margin expansion initiatives and favorable foreign currency translation, offset in part by increased sales and service investments.

### Liquidity and Capital Resources

Liquidity is our ability to generate sufficient cash flows from operating activities to meet our obligations and commitments. In addition, liquidity includes the ability to obtain appropriate financing. Currently, our financing requirements are primarily driven by working capital requirements, capital expenditures, share repurchases and acquisitions.

Cash provided by operating activities totaled $216.8 million during the six months ended June 30, 2018, compared to $205.4 million in the corresponding period in 2017. The increase in 2018 is primarily related to higher net income of $10.7 million, offset in part by a Transition Tax payment of $4.2 million (see below).

Capital expenditures are made primarily for investments in information systems and technology, machinery, equipment and the purchase and expansion of facilities. Our capital expenditures totaled $61.6 million for the six months ended June 30, 2018 compared to $48.5 million in the corresponding period in 2017. The increase is primarily related to investments in manufacturing facilities. We expect to make net investments in new or expanded manufacturing facilities of $20 million to $30 million over the next two years.

In 2017, we recorded a provisional one-time charge of $72 million for the estimated income tax effect of the Transition Tax associated with the Tax Cuts and Jobs Act of which $59 million is expected to be paid over a period of up to eight years. In April 2018, we paid our first Transition Tax payment of $4.2 million.

We plan to repatriate earnings from China, Switzerland, Germany, the United Kingdom and certain other countries in future years and expect the only additional cost associated with the repatriation of such earnings outside the United States will be any applicable withholding taxes. All other undistributed earnings are considered to be permanently reinvested. As of June 30, 2018, we have an immaterial amount of cash and cash equivalents outside the United States where undistributed earnings are considered permanently reinvested. Accordingly, we believe the tax impact associated with repatriating our undistributed foreign earnings will not have a material effect on our liquidity.

#### Senior Notes and Credit Facility Agreement

Our debt consisted of the following at June 30, 2018:

|  | June 30, 2018 U.S. Dollar | Other Principal Trading Currencies | Total |
| --- | ---: | ---: | ---: |
| $50 million Senior Notes, interest 3.67%, due December 17, 2022 | 50,000 | — | 50,000 |
| $50 million Senior Notes, interest 4.10%, due September 19, 2023 | 50,000 | — | 50,000 |
| $125 million Senior Notes, interest 3.84%, due September 19, 2024 | 125,000 | — | 125,000 |
| $125 million Senior Notes, interest 4.24%, due June 25, 2025 | 125,000 | — | 125,000 |
| EUR 125 million Senior Notes, interest 1.47%, due June 17, 2030 | — | 145,163 | 145,163 |
| Debt issuance costs, net | (994) | (342) | (1,336) |
| Total Senior Notes | 349,006 | 144,821 | 493,827 |
| $1.1 billion Credit Agreement, interest at LIBOR plus 87.5 basis points | 469,719 | 56,874 | 526,593 |
| Other local arrangements | 359 | 51,693 | 52,052 |
| Total debt | 819,084 | 253,388 | 1,072,472 |
| Less: current portion | (359) | (51,693) | (52,052) |
| Total long-term debt | $818,725 | $201,695 | $1,020,420 |

On June 15, 2018 we entered into an amended $1.1 billion Credit Agreement (the "Credit Agreement"), which amended our $800 million Amended and Restated Credit Agreement (the "Prior Credit Agreement"), that is further described in Note 7 of our consolidated financial statements.

As of June 30, 2018, approximately $566.9 million was available under the Credit Agreement. Changes in exchange rates between the currencies in which we generate cash flows and the currencies in which our borrowings are denominated affect our liquidity. In addition, because we borrow in a variety of currencies, our debt balances fluctuate due to changes in exchange rates.

In April 2018, two of our non-U.S. pension plans issued loans totaling $39.6 million (Swiss franc 38 million) to our wholly owned subsidiary. The loans have the same terms and conditions which include an interest rate of Swiss franc LIBOR plus 87.5 basis points and a maturity date of April 2019 and a one year renewal term and, as such, are classified as short-term debt on our consolidated balance sheet. The proceeds were used to repay outstanding amounts on our credit facility.

We currently believe that cash flow from operating activities, together with liquidity available under our credit facility and local working capital facilities, will be sufficient to fund currently anticipated working capital needs and capital spending requirements for at least the foreseeable future.

We continue to explore potential acquisitions. In connection with any acquisition, we may incur additional indebtedness.

#### Share Repurchase Program

We have a share repurchase program of which there was $345.9 million of remaining common share to be repurchased under the program as of June 30, 2018. The share repurchases are expected to be funded from cash generated from operating activities, borrowings, and existing cash balances. Repurchases will be made through open market transactions, and the amount and timing of purchases will depend on business and market conditions, stock price, trading restrictions, the level of acquisition activity, and other factors.

We have purchased 27.1 million shares since the inception of the program through June 30, 2018. During the six months ended June 30, 2018 and 2017, we spent $237.5 million and $249.9 million on the repurchase of 396,218 and 505,593 shares at an average price per share of $599.40 and $494.35, respectively. We also reissued 68,653 shares and 153,413 shares held in treasury for the exercise of stock options and restricted stock units during the six months ended June 30, 2018 and 2017, respectively.

### Effect of Currency on Results of Operations

Our earnings are affected by changing exchange rates. We are most sensitive to changes in the exchange rates between the Swiss franc, euro, and U.S. dollar. We have more Swiss franc expenses than we do Swiss franc sales because we develop and manufacture products in Switzerland that we sell globally, and have a number of corporate functions located in Switzerland. When the Swiss franc strengthens against our other trading currencies, particularly the U.S. dollar and euro, our earnings go down. We also have significantly more sales in the euro than we do expenses. When the euro weakens against the U.S. dollar and Swiss franc, our earnings also go down. We estimate a 1% strengthening of the Swiss franc against the euro would reduce our earnings before tax by approximately $1.6 million to $1.8 million annually.

We also conduct business in many geographies throughout the world, including Asia Pacific, the United Kingdom, Eastern Europe, Latin America, and Canada. Fluctuations in these currency exchange rates against the U.S. dollar can also affect our operating results. The most significant of these currency exposures is the Chinese Renminbi. The impact on our earnings before tax of the Chinese Renminbi weakening 1% against the U.S. dollar is a reduction of approximately $1.1 million to $1.3 million annually.

In addition to the effects of exchange rate movements on operating profits, our debt levels can fluctuate due to changes in exchange rates, particularly between the U.S. dollar and the Swiss franc. Based on our outstanding debt at June 30, 2018, we estimate that a 10% weakening of the U.S. dollar against the currencies in which our debt is denominated would result in an increase of approximately $28.2 million in the reported U.S. dollar value of our debt.

### Forward-Looking Statements Disclaimer

*You should not rely on forward-looking statements to predict our actual results. Our actual results or performance may be materially different than reflected in forward-looking statements because of various risks and uncertainties. You can identify forward-looking statements by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or “continue”.*

*We make forward-looking statements about future events or our future financial performance, including earnings and sales growth, earnings per share, strategic plans and contingency plans, growth opportunities or economic downturns, our ability to respond to changes in market conditions, planned research and development efforts and product introductions, adequacy of facilities, access to and the costs of raw materials, shipping and supplier costs, gross margins, customer demand, our competitive position , capital expenditures, cash flow, tax-related matters, compliance with laws, and effects of acquisitions.*

*Our forward-looking statements may not be accurate or complete, and we do not intend to update or revise them in light of actual results. New risks also periodically arise. Please consider the risks and factors that could cause our results to differ materially from what is described in our forward-looking statements. See in particular “Factors Affecting Our Future Operating Results” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our 2017 Annual Report on Form 10-K.*

## Market risk

As filed, 173 characters.

As of June 30, 2018, there was no material change in the information provided under Item 7A in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

## Controls and procedures

As filed, 703 characters.

Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures as required by Exchange Act Rule 13a-15(b) as of the end of the period covered by this report. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer, have concluded that these disclosure controls and procedures are effective. There were no changes in our internal control over financial reporting during the quarter ended June 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 198 characters.

For the six months ended June 30, 2018 there were no material changes from risk factors disclosed in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

Filed Jul 27, 2018.
Source: SEC EDGAR, the filing index for accession 0001037646-18-000026. Last ingested by Listed: Nov 13, 2026, 02:43 ET. No prices; not investment advice.
